PD-L2 overexpression on tumor-associated macrophages is one of the predictors for better prognosis in lung adenocarcinoma.
Adenocarcinoma
Lung cancer
Macrophage
PD-L2
Tumor microenvironment
Journal
Medical molecular morphology
ISSN: 1860-1499
Titre abrégé: Med Mol Morphol
Pays: Japan
ID NLM: 101239023
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
18
05
2023
accepted:
14
06
2023
medline:
20
11
2023
pubmed:
4
7
2023
entrez:
4
7
2023
Statut:
ppublish
Résumé
Immunotherapies that target programmed cell death protein 1 (PD-1) signals are standard therapies for advanced-stage lung cancer, and the expression of programmed death-ligand 1 (PD-L1) in cancer tissue predicts immunotherapy efficacy. Although programmed death-ligand 2 (PD-L2) is expressed in cancer cells and macrophages, similar to PD-L1, its significance in lung cancer is unclear. Double immunohistochemistry analyses using anti-PD-L2 and anti-PU.1 antibodies were carried out on tissue array sections from 231 cases of lung adenocarcinoma, and PD-L2 expression in macrophages was evaluated. High PD-L2 expression in macrophages was associated with longer progression-free survival (PFS) and cancer-specific survival (CSS) and observed more often in females, non-heavy smokers, and patients with epidermal growth factor receptor (EGFR) mutations and those at a lower disease stage. Significant correlations were found more frequently in patients with EGFR mutations. Cell culture studies revealed that cancer cell-derived soluble factors induced PD-L2 overexpression in macrophages, suggesting the involvement of the JAK-STAT signaling pathway. The present findings suggest that PD-L2 expression in macrophages predicts PFS and CSS in lung adenocarcinoma without immunotherapy.
Identifiants
pubmed: 37402054
doi: 10.1007/s00795-023-00361-0
pii: 10.1007/s00795-023-00361-0
doi:
Substances chimiques
B7-H1 Antigen
0
ErbB Receptors
EC 2.7.10.1
PDCD1LG2 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
250-256Subventions
Organisme : Japan Society for the Promotion of Science London
ID : 16H05162
Organisme : Japan Society for the Promotion of Science London
ID : 20H03459
Informations de copyright
© 2023. The Author(s) under exclusive licence to The Japanese Society for Clinical Molecular Morphology.
Références
Hoffman PC, Mauer AM, Vokes EE (2000) Lung cancer. Lancet 355(9202):479–485
doi: 10.1016/S0140-6736(00)82038-3
pubmed: 10841143
Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS (2021) Lung cancer. Lancet 398(10299):535–554
doi: 10.1016/S0140-6736(21)00312-3
pubmed: 34273294
Reck M, Rodríguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823–1833
doi: 10.1056/NEJMoa1606774
pubmed: 27718847
Hellmann MD, Paz-Ares L, Caro RB et al (2020) Atezolizumab for first-line treatment of PD-L1 selected patients with NSCLC. N Engl J Med 383(14):1328–1339
doi: 10.1056/NEJMoa1917346
Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264
doi: 10.1038/nrc3239
pubmed: 22437870
pmcid: 4856023
Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020;367(6477):eaax0182.
Koomen BM, Badrising SK, Heuvel MM, Willems SM (2020) Comparability of PD-L1 immunohistochemistry assays for non-small-cell lung cancer: a systematic review. Histopathology 76(6):793–802
doi: 10.1111/his.14040
pubmed: 31793055
pmcid: 7318295
Herbst RS, Soria JC, Kowanetz M et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528):563–567
doi: 10.1038/nature14011
pubmed: 25428504
pmcid: 4836193
Shinchi Y, Komohara Y, Yonemitsu K et al (2019) Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: a retrospective study by double immunohistochemistry. Cancer Sci 110(9):2711–2721
doi: 10.1111/cas.14128
pubmed: 31294893
pmcid: 6726681
Kozuma Y, Takada K, Toyokawa G, Kohashi K, Shimokawa M, Hirai F, Tagawa T, Okamoto T, Oda Y, Maehara Y (2018) Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma. Eur J Cancer 101:20–29
doi: 10.1016/j.ejca.2018.06.020
pubmed: 30014971
Horlad H, Ma C, Yano H et al (2016) An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma. Cancer Sci 107(11):1696–1704
doi: 10.1111/cas.13065
pubmed: 27564404
pmcid: 5132271
Shinchi Y, Ishizuka S, Komohara Y et al (2022) The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma. Cancer Immunol Immunother 71(11):2645–2661
doi: 10.1007/s00262-022-03187-4
pubmed: 35352168
pmcid: 8963674
Komohara Y, Fujiwara Y, Ohnishi K, Takeya M (2016) Tumor-associated macrophages: potential therapeutic targets for anti-cancer therapy. Adv Drug Deliv Rev 99:180–185
doi: 10.1016/j.addr.2015.11.009
pubmed: 26621196
Matsubara E, Komohara Y, Shinchi Y et al (2021) CD163-positive cancer cells are a predictor of a worse clinical course in lung adenocarcinoma. Pathol Int 71(10):666–673
doi: 10.1111/pin.13144
pubmed: 34231937
Matsubara E, Komohara Y, Esumi S et al (2022) SPP1 derived from macrophages is associated with a worse clinical course and chemo-resistance in lung adenocarcinoma. Cancers 14(18):4374
doi: 10.3390/cancers14184374
pubmed: 36139536
pmcid: 9496817
Y, Kanda. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.
Kovaleva OV, Rashidova MA, Samoilova DV, Podlesnaya PA, Mochalnikova VV, Gratchev A (2020) Immunosuppressive phenotype of esophagus tumors stroma. Anal Cell Pathol 2020:5424780
doi: 10.1155/2020/5424780
Wang Y, Du J, Gao Z, Sun H, Mei M, Wang Y, Ren Y, Zhou X. Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy. Br J Cancer. 2022; Online ahead of print.
Zerdes I, Matikas A, Bergh J, Rassidakis GZ, Foukakis T (2018) Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. Oncogene 37(34):4639–4661
doi: 10.1038/s41388-018-0303-3
pubmed: 29765155
pmcid: 6107481
Matsusaka K, Fujiwara Y, Pan C et al (2021) α
doi: 10.1158/0008-5472.CAN-20-3471
pubmed: 34210751
Umezu D, Okada N, Sakoda Y, Adachi K, Ojima T, Yamaue H, Eto M, Tamada K (2019) Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment. Cancer Immunol Immunother 68(2):201–211
doi: 10.1007/s00262-018-2263-4
pubmed: 30357491
Yonemitsu K, Pan C, Fujiwara Y, Miyasato Y, Shiota T, Yano H, Hosaka S, Tamada K, Yamamoto Y, Komohara K (2022) GM-CSF derived from the inflammatory microenvironment potentially enhanced PD-L1 expression on tumor-associated macrophages in human breast cancer. Sci Rep 12(1):12007
doi: 10.1038/s41598-022-16080-y
pubmed: 35835809
pmcid: 9283541
Li A, Wu W, Deng S et al (2022) Expression of programmed death ligand-2 is associated with prognosis in nasopharyngeal carcinoma microenvironment. J Cancer 13(15):3606–3614
doi: 10.7150/jca.77643
pubmed: 36606190
pmcid: 9809305
Davidson C, Taggart D, Sims AH, Lonergan DW, Canel M, Serrels A (2022) FAK promotes stromal PD-L2 expression associated with poor survival in pancreatic cancer. Br J Cancer 127(10):1893–1905
doi: 10.1038/s41416-022-01966-5
pubmed: 36138073
pmcid: 9643373
Komohara Y, Fujiwara Y, Ohnishi K, Takeya M (2016) Tumor-associated macrophages: potential therapeutic targets for anti-cancer therapy. Adv Drug Deliv Rev 99(Pt B):180–185
doi: 10.1016/j.addr.2015.11.009
pubmed: 26621196
Cassetta L, Pollard JW (2018) Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov 17(12):887–904
doi: 10.1038/nrd.2018.169
pubmed: 30361552
Komohara Y, Kurotaki D, Tsukamoto H et al (2023) Involvement of protumor macrophages in breast cancer progression and characterization of macrophage phenotypes. Cancer Sci 114(6):2220–2229
doi: 10.1111/cas.15751
pubmed: 36748310
pmcid: 10236637